XML 63 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION - Schedule of Disaggregation of Total Net Product Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Revenue $ 648,833 $ 596,415
ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue 35,262 34,403
Product    
Disaggregation of Revenue [Line Items]    
Revenue 637,815 586,426
Marketed by Company | Products excluding ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue 602,553 552,023
Marketed by Company | Products excluding ALDURAZYME | United States    
Disaggregation of Revenue [Line Items]    
Revenue 192,999 166,761
Marketed by Company | Products excluding ALDURAZYME | Europe    
Disaggregation of Revenue [Line Items]    
Revenue 195,748 160,692
Marketed by Company | Products excluding ALDURAZYME | Latin America    
Disaggregation of Revenue [Line Items]    
Revenue 78,594 67,748
Marketed by Company | Products excluding ALDURAZYME | Middle East    
Disaggregation of Revenue [Line Items]    
Revenue 57,075 91,642
Marketed by Company | Products excluding ALDURAZYME | Rest of world    
Disaggregation of Revenue [Line Items]    
Revenue 78,137 65,180
Marketed by Sanofi | ALDURAZYME    
Disaggregation of Revenue [Line Items]    
Revenue $ 35,262 $ 34,403